Full Text Full Text (PDF) Correction: Patient Mean Age Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Kreyenbuhl, J. Articles by Olfson, M. Search for Related Content PubMed Citation Articles by Kreyenbuhl, J. Articles by Olfson, M. Other Health Services Issues Schizophrenia Spectrum Disorders Atypical Neuroleptics Conventional Neuroleptics

Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia

OBJECTIVE: This study compared patients with schizophrenia whose antipsychotic medications were switched to manage treatment-resistant positive psychotic symptoms with those for whom another antipsychotic was added. Psychiatrists' characteristics and perceptions of effectiveness of the medication change on clinical outcomes were also reported. METHODS: Psychiatrists participating in a nationally representative mailed survey (N=209) reported on the clinical features, management, and response to the change in antipsychotic medication (added versus switched) of one adult patient with treatment-refractory schizophrenia under their care for at least one year. RESULTS: Thirty-three percent of patients were treated with an added antipsychotic medication. Compared with patients whose antipsychotic medications were switched, those with an added antipsychotic medication were more likely to be female, to have received care from the same psychiatrist for more than two years, and to have been recently prescribed an antidepressant. Compared with psychiatrists who switched antipsychotic prescriptions, those who added an antipsychotic reported that the change was less likely to reduce positive symptoms, improve functioning, and prevent hospitalization. Psychiatrists who added rather than switched antipsychotics reported more frequent attendance at educational programs sponsored by a pharmaceutical company. CONCLUSIONS: Consistent with other lines of research and practice guideline recommendations, psychiatrists perceive antipsychotic polypharmacy to be a generally ineffective strategy for treatment-resistant positive psychotic symptoms. In light of these findings, efforts to identify and implement more effective evidence-based pharmacologic approaches should be undertaken.

This article has been cited by other articles:

				M. R. Arbuckle, M. J. Gameroff, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Brief Reports: Psychiatric Opinion and Antipsychotic Selection in the Management of Schizophrenia Psychiatr Serv, May 1, 2008; 59(5): 561 - 565. [Abstract] [Full Text] [PDF]

				Bibliography Schizophrenia Focus, January 1, 2008; 6(2): 197 - 199. [Full Text] [PDF]

				J. E. Hovens and A. J. M. Loonen Adding and Switching Antipsychotics Psychiatr Serv, October 1, 2007; 58(10): 1375 - 1375. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us